No Detail Found!

Role of Low Molecular Weight Heparin in Unexplained Recurrent Pregnancy Loss

Author(s)
Rashida Parveen Department of Obstetrics and Gynaecology, DG Khan Medical College,Dera Ghazi Khan,Pakistan
Hajra Sultana Department of Obstetrics and Gynaecology, Nishtar Medical University and Hospital,Multan,Pakistan
Aisha Siddiqa Department of Obstetrics and Gynaecology, DG Khan Medical College,Dera Ghazi Khan,Pakistan
Abstract
To evaluate the e ectiveness of low molecular weight heparin (LMWH) in unexplained recurrent pregnancy loss (URPL). Study Design: Open-labelled, single-centre, randomised controlled trial. Place and Duration of the Study: Department of Obstetrics and Gynaecology, DG Khan Hospital, Dera Ghazi Khan, Pakistan, from June 2023 to December 2024. Methodology: One hundred and seventy pregnant women aged 18-44 years with a gestational age exceeding 8 weeks and a history of three or more consecutive rst-trimester pregnancy losses were randomly assigned to one of two groups using the sealed envelope lottery method. The LMWH group (n = 85) received a daily subcutaneous injection of 40 mg LMWH, while the placebo group (n = 85) was given a multivitamin tablet as a placebo. The primary outcome was assessed in terms of e cacy, de ned as live births occurring after reaching 24 weeks of gestation. Secondary outcomes included both maternal and foetal health outcomes. Numeric data were compared by applying the Mann-Whitney U test, while categorical data were compared by employing the Chisquare test. For all inferential statistics, a value of p <0.05 was considered statistically signi cant. Results: In a total of 170 women, the median age was 32.00 (30.00-35.00) years. In the LMWH group, the proportion of live-births was 88.0% versus 73.4% in the placebo group (p = 0.019). It was found that the proportion of caesarean section was signi cantly higher among women of the LMWH group (72.6% vs. 51.7%, p = 0.014). The proportion of premature birth was signi cantly high in placebo group (25.9% vs. 9.6%, p = 0.013). Conclusion: This study demonstrates that the LMWH is associated with a signi cantly higher live birth rate in women with RPL, without increasing the risk of adverse maternal and neonatal outcomes.
Publication Details
Page(s) 717-721
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 06, Year: 2025

Request the full text from PASTIC

Keywords
Heparin, Gestational Age, Placebo, Low birrth weight, Pregnancy loss
References
Turesheva A,Aimagambetova G,Ukybassova T,Marat A,Kanabekova P,Kaldygulova L .2023 .Recurrent pregnancy loss etiology, risk factors, diagnosis, and management. Fresh look into a full box. J Clin Med, 10(12) : 4074.
Li Q,Chen S,Dong X,Fu S,Zhang T,Zheng W .2023 .The progress of research on genetic factors of recurrent pregnancy loss. Genet Res (Camb), 10 : .
Tomkiewicz J,Darmochwal-Kolarz D. .2023 .The diagnostics and treatment of recurrent pregnancy loss. J Clin Med, 10(14) : 4768.
Deng T,Liao X,Zhu S. .2022 .Recent advances in treatment of recurrent spontaneous abortion. Obstet Gynecol Surv, 10(6) : 355-66.
Awolumate OJ,Kang A,Khokale R,Cancarevic I. .2020 .Role of low molecular weight heparin in the management of unexplained recurrent pregnancy loss: A review of literature. Cureus, 10(10) : .
Kornacki J,Gutaj P,Kalantarova A,Sibiak R,Jankowski M,Wender-Ozegowska E .2021 .Endothelial dysfunction in pregnancy complications. Biomedicines, 10(12) : 1756.
Sah AK,Shrestha N,Joshi P,Lakha R,Shrestha S,Sharma L .2018 .Association of parental methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism in couples with unexplained recurrent pregnancy loss. BMC Res Notes, 10(1) : 233.
Banik N,Yang SB,Kang TB,Lim JH,Park J .2021 .Heparin and its derivatives: Challenges and advances in therapeutic biomolecules. Int J Mol Sci, 10(19) : 10524.
Bai W,Zhang X,Sun S,Wang Q,Li C .2021 .E ect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: A single-centre, observational study. BMC Pregnancy Childbirth, 10(1) : 683.
Green D,Hirsh J,Heit J,Prins M,Davidson B,Lensing AW .1994 .Low molecular weight heparin: A critical analysis of clinical trials. Pharmacol Rev, 46(1) : 89-109.
Shute JK .2023 .low molecular weight heparin, and nonanticoagulant derivatives for the treatment of in ammatory lung disease. Pharmaceuticals (Basel), 10(4) : 584.
Khan ES,Basharat A,Jamil M,Ayub S,Khan MA .2017 .Preventive role of low-molecular-weight heparin in unexplained recurrent pregnancy loss. South Afr J Obstet Gynecol, 23(1) : 17-9.
Yuksel H,Kayatas S,Boza AT,Api M,Ertekin AA,Cam C .2014 .Low molecular weight heparin use in unexplained recurrent miscarriage. Pak J Med Sci, 10(6) : 1232-7.
Abbattista M,Capecchi M,Gianniello F,Artoni A,Bucciarelli P,Ciavarella A .2023 .A retrospective study on the use of low- molecular-weight heparin for prevention of pregnancy-related recurrent venous thromboembolism and obstetrical complications. Blood Coagul Fibrinolysis, 10(2) : 111-7.
Zhao L,Bi S,Fu J,Qi L,Li L,Fu Y .2021 .Retrospective analysis of fondaparinux and low-molecular-weight heparin in the treatment of women with recurrent spontaneous abortion. Front Endocrinol (Lausanne), 717630 : 717630.
Mantha S,Bauer KA,Zwicker JI .2009 .Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: A systematic review. J Thromb Haemost, 03687(2) : 7836-8.
Clark P,Walker ID,Langhorne P,Crichton L,Thomson A,Greaves M .2010 .SPIN (Scottish Pregnancy Intervention) study: A multicentre, randomised controlled trial of lowmolecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. -01-267252., 10(21) : 4162-7.
Kaandorp SP,Goddijn M,van der Post JA,Hutten BA,Verhoeve HR,Hamulyak K .2010 .Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med, 10(17) : 1586-96.
Schleussner E,Kamin G,Seliger G,Rogenhofer N,Ebner S,Toth B .2015 .Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: A multicentre trial with a minimization randomization scheme. Ann Intern Med, 10(9) : 601-9.
Arachchillage DJ,Kitchen S. Pleiotropic .2024 .e ects of heparin and its monitoring in the clinical practice. Semin Thromb Hemost, 10(8) : 1153-62.
.2018 .ACOG practice bulletin no. 196: Thromboembolism in pregnancy. Obstet Gynecol, 10(1) : 000000000-0002706.
0

Citations

0

Downloads

38

Views